anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Among cervical adenocarcinomas, well-differentiated gastric adenocarcinoma of the uterine cervix (WD-GAS), previously termed adenoma malignum (minimal deviation adenocarcinoma) is not well understood. Because of its rarity and difficulty in diagnosis, there is no standard care for WD-GAS. Thus, we conducted the first multicenter retrospective study on WD-GAS to clarify prognostic factors for long-term survival and recurrence.
METHODS: Patients diagnosed with WD-GAS at eight hospitals participated in this multi-center study. Overall survival (OS) and recurrence-free survival (RFS) were calculated with the Kaplan-Meier method. Additionally, OS between the early and advanced FIGO stage groups were compared with the log-rank test. Cox regression analysis was conducted to identify significant factors associated with recurrence-free survival (RFS).
RESULTS: A total of 73 patients from eight hospitals in South Korea were included in the analysis. The median follow-up period was 44.8 months, and all patients underwent curative surgical intervention as the primary treatment. Recurrence was observed in 17 patients (23.3%). Ten patients had locoregional recurrence, four patients had distant metastasis, and three patients presented with both locoregional recurrence and distant metastasis. The Cox regression analysis identified several statistically significant factors associated with RFS, including vaginal invasion (VI), parametrial invasion (PMI), resection margin (RM), and nodal and lymphovascular invasion (LVI). When considering these five factors together, patients without any of the factors exhibited recurrence-free survival (RFS) of 97.0% at three years and those with more than one of these factors had a 3-year RFS of 65.4% (P < 0.001).
CONCLUSION: WD-GAS showed relatively high locoregional recurrence rate. Positive PMI, VI, RM, nodal involvement, and LVI were associated with a significant increase in recurrence or distant metastasis rates.
The folate receptor alpha protein is important in tumor growth and can be over-expressed in some tumor cells. The word "over-expressed" in this situation means that there are too many copies of the protein on the surface of the cell when compared to a healthy, normal cell, and this helps the tumor continue to grow in size. Mirvetuximab soravtansine acts by targeting the folate receptor in tumor cells. In animal models, mirvetuximab soravtansine is highly effective in decreasing tumor size. This suggests that mirvetuximab soravtansine may help shrink or stop growth of folate receptor alpha positive breast cancer in this study.

In this study the investigator will be looking at how folate receptor alpha expression changes following 2 doses of neoadjuvant mirvetuximab soravtansine. The investigator will also look to evaluate the safety of this regimen, measure any change in tumor size, associate folate receptor alpha expression with a change in tumor size, and describe any changes in Ki-67 and percent of apoptotic cells in this population.
Methods, systems, computer-readable media, and apparatuses for capturing and managing healthcare information are presented. In one or more embodiments, a server computing device may establish a first network connection to a first bedside computing device. Subsequently, the server computing device may select a first device profile for the first bedside computing device. The server computing device then may provide the first device profile to the first bedside computing device. Thereafter, the server computing device may establish a second network connection to a second bedside computing device different from the first bedside computing device. Subsequently, the server computing device may select a second device profile for the second bedside computing device.
Twin and family studies have established the genetic contribution to idiopathic generalized epilepsy (IGE). The genetic architecture of IGE is generally complex and heterogeneous, and the majority of the genetic burden in IGE remains unsolved. We hypothesize that gene-gene interactions contribute to the complex inheritance of IGE. CNTN2 (OMIM* 615,400) variants have been identified in cases with familial adult myoclonic epilepsy and other epilepsies. To explore the gene-gene interaction network in IGE, we took the CNTN2 gene as an example and investigated its co-occurrent genetic variants in IGE cases. We performed whole-exome sequencing in 114 unrelated IGE cases and 296 healthy controls. Variants were qualified with sequencing quality, minor allele frequency, in silico prediction, genetic phenotype, and recurrent case numbers. The STRING_TOP25 gene interaction network analysis was introduced with the bait gene CNTN2 (denoted as A). The gene-gene interaction pair mode was presumed to be A + c, A + d, A + e, with a leading gene A, or A + B + f, A + B + g, A + B + h, with a double-gene A + B, or other combinations. We compared the number of gene interaction pairs between the case and control groups. We identified three pairs in the case group, CNTN2 + PTPN18, CNTN2 + CNTN1 + ANK2 + ANK3 + SNTG2, and CNTN2 + PTPRZ1, while we did not discover any pairs in the control group. The number of gene interaction pairs in the case group was much more than in the control group (p = 0.021). Taking together the genetic bioinformatics, reported epilepsy cases, and statistical evidence in the study, we supposed CNTN2 as a candidate pathogenic gene for IGE. The gene interaction network analysis might help screen candidate genes for IGE or other complex genetic disorders.
Safety and efficacy of almotriptan malate in pediatric patients under the age of 12 years have not been established. The pharmacokinetics, efficacy, and safety of almotriptan malate have been evaluated in adolescent patients, age 12 to 17 years [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)]. 

In a clinical study, almotriptan 6.25 mg and 12.5 mg were found to be effective for the relief of migraine headache pain in adolescent patients age 12 to 17 years. Efficacy on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. The most common adverse reactions (incidence of ≥ 1%) associated with almotriptan malate treatment were dizziness, somnolence, headache, paresthesia, nausea, and vomiting [see Adverse Reactions (6.1)]. The safety and tolerability profile of almotriptan malate treatment in adolescents is similar to the profile observed in adults. 

Postmarketing experience with other triptans include a limited number of reports that describe pediatric patients who have experienced clinically serious adverse events that are similar in nature to those reported rarely in adults.
Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose expansion cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.
Partial reddish swelling hot pain acute inflammation is a clinical usual symptom. In order to prevent partial reddish swelling hot pain acute inflammation from changing into chronic inflammation and quickly cure partial reddish swelling hot pain acute inflammation, 13 kinds of traditional Chinese medicinal materials with the functions of blood circulation promotion and blood stasis removal, such as safflower, red sage root, red peony root, etc., are used. According to medicine theories and modern medicine backgrounds in China and through longtime clinical practice, repeating sieving and the innovation of preparation technologies, firstly, effective components are respectively extracted through a water phase and an oil phase, and then, the effective components are synthesized into an oil-in-water type external use ointment. Through the confirmation of 16 base medicine experiments, and after being partially coated, the oil-in-water type external use ointment can quickly improve microcirculation, enhance the activity of metabolic enzymes, increase muscle glycogen and activate macrophages. The oil-in-water type external use ointment can accelerate partial inflammation purification, and enhance tissue regeneration capability. Therefore, the oil-in-water type external use ointment can remove swelling of severe contusion of the Quanfu points within average 3 to 4 days, and the clinical cure of swelling of severe contusion of the Quanfu points can be realized after the oil-in-water type external use ointment is used for 4 to 6 days. The curative effects of the oil-in-water type external use ointment are obviously better than a control group (Pangle0.01). Through the clinical observation of 671 cases of 12 medical units, such as PLA General Hospital, etc., the total effective rate reaches 98.7%, painful swelling is removed within 3 to 4 days, and functions get right.
Allogeneic stem cell transplants (SCT) can induce curative Graft versus Tumor (GvT) reactivities in patients with hematological malignancies. The GvT  reaction is mainly mediated by allo immune donor T-cells specific for polymorphic minor Histocompatibility antigens (mHags). Among these, the mHag HA-1 was found to be restricted to the hematopoietic system. Here we report the expression of HA-1 by non-hematopoietic tumor cells. While absent in normal epithelial cells, tumor cells and tumor cell lines particularly from epithelial origin, also express HA-1 and are recognized by HA-1 cytotoxic T  cells. The invention provides, among others, means and methods for HA-1 specific immunotherapy for HA-1 positive patients with non-hematopoietic tumor cells.
A novel adhesive formed in situ in a microcapsule and method for forming such a pressure sensitive or flowable adhesive in situ in a microcapsule is disclosed. The method for forming the novel adhesive comprises providing an aqueous mixture of wall material in water; adding a substantially water insoluble core material, free radical initiator, and a solvent for the pre-polymers to the aqueous mixture. The core material comprises a first addition polymerizable pre-polymer having a Tg of less than about 0° C., a flash point of at least 75° C., and a boiling point of at least 175° C. These are typically selected from acrylate or methacrylate type materials. Optionally included is a second addition polymerizable pre-polymer for providing cross-linking or interaction between polymer chains. High shear agitation is provided to the aqueous mixture to achieve a particle size of about 0.1 to 250 microns. Stirring at a first temperature effects capsule wall formation; and heating to a second temperature polymerizes the pre-polymers of the core material to form an adhesive in situ in the formed capsules.
In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
The present invention relates to a human truncation type recombinant soluble TRAIL-170 protein which is a TRAIL protein segment containing amino acids 112-281. An N terminal of the primary structure of the protein is proline, and a C terminal is glycine, wherein the primary structure of the protein contains 11 arginines, 6 histidines, 11 lysines and one and a half cystines; an isoelectric point PI is 9.27; the protein is an alkali protein. The secondary structure of the protein contains two antiparallel beta sheet layers. The cDNA sequence of the protein is composed of 510 nucleotides, and 170 amino acids are coded. The protein can obviously induce the apoptosis of tumor cells, kills or/and restrains the growth of tumour cells in animals. Compared with a TRAIL95-281 segment generally used internationally, the human truncation type recombinant soluble TRAIL-170 protein of the present invention has the characteristics of small molecular weight and high activity. The present invention has wide application prospect in preparing medicine for treating tumors.
Baicalin (BAN) has shown promise in alleviating myocardial ischemia/reperfusion (I/R) injury, yet its limited solubility and biocompatibility have hindered its application. Developing drug delivery systems is a promising strategy to enhance the therapeutic potential of BAN in the context of I/R injury. This study aims to prepare a BAN-loaded nanodrug system using polydopamine (PDA)-modified Zeolitic imidazolate framework-8 (ZIF-8) as a carrier, with the goal of improving BAN's mitigating effects on I/R injury. We prepared the BAN nanoparticles (NPs) system, PZB NPs, using ZIF-8 as the carrier. The system was characterized in terms of morphology, particle size, zeta potential, and X-ray diffraction (XRD). We assessed the cytotoxicity of PZB NPs in H9c2 cells, investigated its effects and mechanisms in H/R-induced H9c2 cells, and evaluated its ability to alleviate myocardial I/R injury in rats. PZB NPs exhibited good dispersion, with a BAN loading efficiency of 26.43 ± 1.55%, a hydrated particle size of 102.21 ± 1.19 nm, and a zeta potential of -24.84 ± 0.07 mV. It displayed slow and sustained drug release in an acidic environment (pH 5.5). In vitro studies revealed that PZB NPs was non-cytotoxic and significantly enhanced the recovery of H/R injury H9c2 cell viability. PZB NPs suppressed cell apoptosis, activated the Nrf2/HO-1 pathway, and cleared ROS. In vivo study demonstrated that PZB NPs significantly reduced infarct size, ameliorated fibrosis and improved heart function. The PZB NPs markedly enhances BAN's ability to alleviate I/R injury, both in vitro and in vivo, offering a promising drug delivery system for clinical applications.
BACKGROUND: Significant concerns have been raised regarding how medications with a risk of dependence or withdrawal are managed and how care is experienced by patients. This study sought to co-design solutions to improve the experience of care for patients prescribed benzodiazepines, z-drugs, opioids for chronic non-cancer pain, gabapentinoids and antidepressants.
METHOD: Twenty patients and fifteen healthcare professionals from five different GP practices were recruited to take part. The study used Experience Based Co-Design. Patients and healthcare professionals completed semi-structured interviews and took part in feedback groups and co-design workshops to collaboratively identify priorities for improvement and to co-design solutions to improve the experience of care.
RESULTS: Poor patient experience was common among people prescribed medications with a risk of dependence or withdrawal. Patients and healthcare professionals identified three main priority areas to improve the experience of care: (i) ensuring patients are provided with detailed information in relation to their medication, (ii) ensuring continuity of care for patients, and (iii) providing alternative treatment options to medication. Solutions to improve care were co-designed by patients and healthcare staff and implemented within participating GP practices to improve the experience of care.
CONCLUSION: Good patient experience is a key element of quality care. This study highlights that the provision of in-depth medication related information, continuity of care and alternative treatment to medication are important to patients prescribed medicines with a risk of dependence or withdrawal. Improving these aspects of care should be a priority for future improvement and delivery plans.
A dental implant made of zirconia ceramic-fused-bioactive glass ceramic artificial bone dust and a preparation method therefor. The implant is of a non-embedded structure and is integrated with a foundation. The upper part of the foundation is provided with a foundation pole, the lower part of the foundation is provided with a foundation pile, and an expanded base plate is arranged between the foundation pole and the foundation pile. When the implant is an anterior tooth implant, the gum-penetrating part of the foundation pile is also provided with an expanded bamboo joint shaped foundation pile joint. The body part and the root part of the implant are provided with threads, the thread of the body part is a shallow trapezoidal thread, and the thread of the root part is a deep triangular thread. The under-neck part of the implant, implanted into an alveolar bone, is fused with bioactive glass ceramic artificial bone dust. The implant has a reasonable design structure, is difficult to break off, has better biocompatibility compared with a pure titanium implant, and has higher bone combination intensity compared with a hydroxyapatite coated implant.
The present invention relates to methods for using a human A Disintegrin And Metalloprotease containing ThromboSpondin repeats (ADAM-TS). The invention also relates to methods for using polynucleotides encoding the metalloprotease. The invention relates to methods using the ADAM-TS  polypeptides and polynucleotides as a target for diagnosis and treatment in metalloprotease-mediated or -related disorders. The invention further relates to drug-screening method using the ADAM-TS polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the ADAM-TS polypeptides and polynucleotides. The invention further relates to antagonists identified by drug screening methods with the ADAM-TS polypeptides and polynucleotides as a target. The invention further related to methods of treating a subject suffering from a ADAM-TS associated disorder.
The invention discloses a series of skin care products with oat protein peptide as a basic component and a preparation method thereof, which belongs to the field of health care. The series of the skin care products overcome the defects of side effects and poor absorption of the conventional skin care products. The series of the skin care products comprise oat protein peptide smoothing toner, oat protein peptide essence, oat protein peptide day cream and oat protein peptide night cream. The raw materials of the series of the skin care products comprise purified water, propylene glycol, oat protein peptide, hyaluronic acid, natural squalane, marine polysaccharide, water-soluble vitamin E, water-soluble jojoba oil, water-soluble lanolin, methyl-p-hydroxy benzoate, propyl p-hydroxybenzoate, hydroxyethyl cellulose and fresh hundred-flower essence. The preparation method comprises the step of preparing the series of the skin care product in the mixing process through emulsification or partial emulsification and partial hydration according to the different products. The series of the skin care product have the following advantages that: oat active peptide can significantly increase the content of collagen in a mechanocyte and inhibit and prevent skin aging, and the cosmetic effect of the series of the skin care products is obviously higher than that of synthetic peptides. The natural hyaluronic acid in the skin care products can obviously increase the permeability of an arterial wall, and improve the adaptability of skin to external environmental changes.
The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in MaxSimil® form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
Embryonic stem (ES) cells are pluripotent stem cells that can produce all cell types of an organism. ES cells proliferate rapidly and are thought to experience high levels of intrinsic replication stress. Here, by investigating replication fork dynamics in substages of S phase, we show that mammalian pluripotent stem cells maintain a slow fork speed and high active origin density throughout the S phase, with little sign of fork pausing. In contrast, the fork speed of non-pluripotent cells is slow at the beginning of S phase, accompanied by increased fork pausing, but thereafter fork pausing rates decline and fork speed rates accelerate in an ATR-dependent manner. Thus, replication fork dynamics within the S phase are distinct between ES and non-ES cells. Nucleoside addition can accelerate fork speed and reduce origin density. However, this causes miscoordination between the completion of DNA replication and cell cycle progression, leading to genome instability. Our study indicates that fork slowing in the pluripotent stem cells is an integral aspect of DNA replication.
The invention locally delivers a chemotherapeutic or a radiographic contrast agent to an upper tract urothelial carcinoma (UTUC). The invention includes a balloon catheter with a working channel and a balloon placed into the ureter/renal pelvis via retrograde or antegrade ureteral access. The balloon is inflated to temporarily obstruct the ureter, and a formulation with a chemotherapeutic agent is infused into the working channel of the catheter and allowed to dwell in the ureter/renal pelvis for a time sufficient to allow the formulation to adhere to and penetrate the urothelial wall. The formulations can be liposomal or non-liposomal formulations. At least portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter/renal pelvis. The methods of the invention can be performed as an adjuvant therapy to other methods of treating UTUC, including ureteroscopic ablation or resection of the tumor.
BACKGROUND: The atherogenic index of plasma (AIP) is considered an independent risk factor for coronary artery disease (CAD). The present study investigated whether AIP correlates with the formation of coronary collateral circulation (CCC) in CAD patients with chronic total occlusion (CTO).
METHODS: This retrospective study included 1093 CAD patients with CTO confirmed by coronary angiography from January 2020 to December 2020 at Beijing Anzhen Hospital. Based on the Rentrop scoring system, the patients were divided into the good CCC group and the poor CCC group. AIP was calculated by log (triglyceride/high-density lipoprotein cholesterol). Meanwhile, the study population was further divided into four groups according to the quartiles of AIP.
RESULTS: Patients in the poor CCC group exhibited significantly higher AIP compared to those in the good CCC group (0.31 ± 0.27 vs. 0.14 ± 0.24, p < 0.001). Multivariate logistic regression analysis revealed an independent association between AIP and poor CCC, regardless of whether AIP was treated as a continuous or categorical variable (p < 0.001), after adjusting for confounding factors. Besides, this association remained consistent across most subgroups. The incorporation of AIP into the baseline model significantly enhanced the accuracy of identifying poor CCC [area under the curve (AUC): baseline model, 0.661 vs. baseline model + AIP, 0.721, p for comparison < 0.001].
CONCLUSIONS: Elevated AIP is independently associated with an increased risk of poor CCC in CAD patients with CTO, and AIP may improve the ability to identify poor CCC in clinical practice.